GLMD Stock Overview
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$5.63 |
| 52 Week Low | US$0.26 |
| Beta | 0.87 |
| 1 Month Change | 0.052% |
| 3 Month Change | 8.06% |
| 1 Year Change | -92.80% |
| 3 Year Change | -98.84% |
| 5 Year Change | -99.63% |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Shareholder Returns
| GLMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 1.3% | 3.3% |
| 1Y | -92.8% | 3.0% | 25.0% |
Return vs Industry: GLMD underperformed the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: GLMD underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| GLMD volatility | |
|---|---|
| GLMD Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GLMD has not had significant price volatility in the past 3 months.
Volatility Over Time: GLMD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Allen Baharaff | www.galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GLMD fundamental statistics | |
|---|---|
| Market cap | US$2.34m |
| Earnings (TTM) | -US$6.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs GLMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.91m |
| Earnings | -US$6.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLMD perform over the long term?
See historical performance and comparison